WeWork India slips 5% in debut trade amid valuation, governance concerns

Shares of WeWork India fell as much as 5.2% on Friday, valuing the flexible workspace operator at Rs 82.32 billion ($927.3 million), as investors stayed wary of its steep valuation and governance risks.

The stock last traded at Rs 634.4, below its offer price of Rs 648.

The listing comes at a busy time for India’s primary market. On Thursday, LG Electronics India was bid 54.02 times, becoming the most subscribed billion-dollar IPO in nearly two decades, while Tata Capital’s IPO drew bids worth $1.24 billion and was subscribed 1.95 times.

WeWork India, which licenses its brand from its now-bankrupt US namesake WeWork Global, raised about $213.7 million and its IPO was subscribed 1.15 times, driven largely by institutional bids.

Beyond a crowded IPO market, WeWork India faces deeper challenges – from corporate governance concerns to questions over its ability to sustain operations and fund expansion amid slowing demand and rising competition from leaner, profitable rivals.

Corporate governance firm InGovern warned investors of WeWork India’s fragile financials, negative cash flow, high lease liabilities, and the absence of fresh capital infusion.

WeWork India did not immediately respond to a request for comment.

The company operates flexible offices across eight major Indian cities, competing with peers such as Smartworks Coworking Spaces, which has gained 35% since its July debut, and IndiQube Spaces, which fell 15% after listing but has since recovered to trade 4% higher.

Smartworks has a market capitalisation of 68.9 billion rupees, while IndiQube is valued at 47.6 billion, according to exchange data.

WeWork India’s weak debut comes amid a historic year for India IPOs. More than 240 large and mid-sized firms raised $10.5 billion in the first nine months of 2025, making India the world’s third-largest IPO market, according to LSEG data.

Latest

Explained: Why stock markets are rising even as crude oil remains above $100

Benchmark indices rallied in early trade on Monday despite crude oil remaining elevated above $100. The move reflected bargain buying and global AI-led optimism

Sun Pharma’s biggest-ever bet: Why markets cheered the Organon mega deal

Sun Pharma just made the biggest bet in Indian pharma history. Markets loved it instantly. Here’s why investors backed the Organon deal despite the massive pr

Cohance Lifesciences hits 20% upper circuit: Why the stock rising today?

Cohance Lifesciences jumped 20% after appointing former Cipla CEO Umang Vohra. Investors are betting his leadership can accelerate growth and transform the comp

Decoding the Sun Pharma $11.75 billion deal: Why the pharma stock jumped 7% today?

The stock was trading around Rs 1,739.70 as of 9:46 am, up over 7%, after touching a high of Rs 1,741.85 during the session, reflecting strong investor interest

Paytm shares tumble 6% today: Is this dip a buying chance for investors?

Paytm shares fell 6% today. Is this panic-driven weakness, or a smart chance for investors to buy into the fintech stock at lower levels now?

Topics

Explained: Why stock markets are rising even as crude oil remains above $100

Benchmark indices rallied in early trade on Monday despite crude oil remaining elevated above $100. The move reflected bargain buying and global AI-led optimism

Sun Pharma’s biggest-ever bet: Why markets cheered the Organon mega deal

Sun Pharma just made the biggest bet in Indian pharma history. Markets loved it instantly. Here’s why investors backed the Organon deal despite the massive pr

Watch out Apple and Samsung, OpenAI is making AI smartphone with agentic capabilities

OpenAI is reportedly working with MediaTek and Qualcomm on smartphone processors, aiming to build an AI-first device powered by agent-led experiences.

ICSE, ISC board results to be out this week? Here’s what CISCE official has to say

The Council for the Indian School Certificate Examinations (CISCE) will declare the much-awaited ICSE Class 10 and ISC Class 12 Results 2026 shortly. Officials

Sam Altman says Codex is causing major FOMO so he changing his sleep schedule

Sam Altman says GPT-5.5 in Codex is so good he’s cutting sleep. He has said due to AI he has switched to polyphasic sleep — a schedule involving multiple sh

Cohance Lifesciences hits 20% upper circuit: Why the stock rising today?

Cohance Lifesciences jumped 20% after appointing former Cipla CEO Umang Vohra. Investors are betting his leadership can accelerate growth and transform the comp

30 students suspended at Hansraj College over fest chaos, DUSU calls it undemocratic

Hansraj College has placed around 30 students, including four elected union office-bearers, under interim suspension over alleged misconduct tied to its annual

Decoding the Sun Pharma $11.75 billion deal: Why the pharma stock jumped 7% today?

The stock was trading around Rs 1,739.70 as of 9:46 am, up over 7%, after touching a high of Rs 1,741.85 during the session, reflecting strong investor interest
spot_img

Related Articles

Popular Categories

spot_imgspot_img